Form 4: Akero CFO Sells Shares Post-Novo Nordisk Merger

Akero Therapeutics' CFO, William Richard White, disposed of common stock, RSUs, and stock options following the company's acquisition by Novo Nordisk.

Summary

• William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (AKRO), reported the disposal of securities.
• The transactions occurred on December 9, 2025, coinciding with the effective time of the merger between Akero Therapeutics and Novo Nordisk A/S, through its subsidiary NN Invest Sub, Inc.
• Akero Therapeutics became a wholly-owned subsidiary of Novo Nordisk A/S as a result of the merger.
• White disposed of 10,179 shares of common stock, 47,573 restricted stock units (RSUs), and 660,579 shares underlying various stock options.
• Each share of common stock and RSU was converted into the right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) representing the right to receive an additional $6.00 in cash if a specified milestone is achieved.
• Each compensatory stock option, whether vested or not, was deemed fully vested and converted into a cash payment equal to the product of the excess of the $54.00 Closing Consideration over the option's per share exercise price, multiplied by the number of shares subject to the option, plus one CVR for each underlying share.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for Akero Therapeutics' shareholders and equity holders, as the merger provides a significant cash payout and potential upside from a CVR, representing a successful exit for the company.

Positives

• Shareholders, RSU holders, and option holders received a cash payment of $54.00 per share/unit/option, representing a clear acquisition premium.
• The inclusion of a Contingent Value Right (CVR) for an additional $6.00 per share offers potential upside if a specified milestone is achieved.

Negatives

• Akero Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Novo Nordisk A/S.

Risks

• The additional $6.00 per share from the Contingent Value Right (CVR) is not guaranteed and is dependent on the achievement of a specified milestone.

Future Outlook

Akero Therapeutics, Inc. will operate as a wholly-owned subsidiary of Novo Nordisk A/S following the completion of the merger.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger companies like Novo Nordisk strategically acquire smaller firms with promising assets to expand their pipelines and market presence.

Comparison to Industry Standards

• This Form 4 filing primarily reports an insider's transaction resulting from a corporate merger and does not provide sufficient financial or operational data to assess Akero Therapeutics' performance against global industry benchmarks or specific comparable companies/projects. The acquisition price itself would be the basis for such a comparison, but the details for that analysis are not within the scope of this filing.

Stakeholder Impact

• Shareholders received cash and CVRs for their common stock, providing a liquidity event and potential future upside.
• Employees holding RSUs and stock options, including the CFO, had their equity converted into cash and CVRs, realizing value from their holdings.
• Akero Therapeutics as a corporate entity transitioned from an independent public company to a subsidiary of Novo Nordisk A/S.

Next Steps

• Akero Therapeutics, Inc. will continue its operations as a wholly-owned subsidiary of Novo Nordisk A/S.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Contingent Value Right, CFO